This trial will test whether the drug ustekinumab is safe and effective for treating people with ichthyosis, a group of lifelong genetic disorders characterized by generalized skin thickening, scaling, and underlying cutaneous inflammation.
2 Primary · 0 Secondary · Reporting Duration: 7 months after initiation of study drug
Side Effects for
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: Ustekinumab · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What clinical indications is Ustekinumab commonly prescribed for?
"Ustekinumab is generally used to regulate the production of adrenal cortex hormones. It may additionally be prescribed as a last resort for conditions such as psoriasis, an inadequate response to one or more tnf antagonist therapies, and severe active Crohn's Disease." - Anonymous Online Contributor
Can you elaborate on any other research trials that have utilized Ustekinumab?
"Currently, 34 trials involving Ustekinumab are ongoing with 17 of those in the final stage. While Warsaw, Mazowieckie is one of the locations for these tests, 2820 other medical sites worldwide are also running studies about this drug." - Anonymous Online Contributor
What is the upper limit of participants enrolled in this medical research?
"That is correct. Clinicaltrials.gov reveals that this research trial, which was initiated on April 1st 2021, requires 15 participants and is currently looking for volunteers from one location." - Anonymous Online Contributor
Are there any openings to join this clinical experiment?
"Indeed, according to the information on clinicaltrials.gov this trial is currently enrolling patients. The initial posting was made April 1st 2021 and has been edited as recently as April 19th 2022. 15 individuals are being sought from a single site." - Anonymous Online Contributor